文献速递慢性肾脏病肾小球疾病

轻至中度COVID-19后的肾脏结局

Kidney outcome after mild to moderate COVID-19.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

这项横断面研究比较了443例非重症COVID-19康复者(中位9个月后)与1328名匹配对照,发现post-COVID-19组平均eGFR轻度较低(β=-1.84,95%CI -3.16至-0.52),但慢性肾脏病、重度白蛋白尿、血尿、脓尿和蛋白尿在两组间相似,Dickkopf3未升高,无持续或进展性肾脏后遗症证据。

要点

  • 非重症COVID-19后中位9个月,平均eGFR较对照轻度降低(β=-1.84,95%CI -3.16至-0.52)。
  • 慢性肾脏病(OR 0.90,95%CI 0.48-1.66)和重度白蛋白尿(OR 0.76,95%CI 0.49-1.09)在两组间无显著差异。
  • Dickkopf3未升高(β=-72.19,95%CI -130.0至-14.4),无持续肾损伤证据。

核心结论

  • 非重症COVID-19后平均eGFR轻度较低,但无证据表明存在持续或进展性肾脏后遗症。

研究设计与样本

  • 横断面研究,研究对象来自德国汉堡城市健康研究(HCHS)及其COVID-19项目,纳入COVID-19后个体并按年龄、性别和教育匹配非COVID-19对照。
  • 共纳入443例非重症COVID-19后个体(中位9个月后)和1328例非COVID-19对照。

主要发现

  • post-COVID-19组平均eGFR较非COVID-19组轻度降低,校正已知危险因素后β=-1.84(95%CI -3.16至-0.52)。
  • 慢性肾脏病在post-COVID-19组与非COVID-19组发生率无显著差异,OR=0.90(95%CI 0.48-1.66)。
  • 重度白蛋白尿在两组间无显著差异,OR=0.76(95%CI 0.49-1.09)。
  • 血尿、脓尿和蛋白尿在两组队列间相似。
  • post-COVID-19队列Dickkopf3未升高,β=-72.19(95%CI -130.0至-14.4)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela. METHODS: This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria. RESULTS: A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)]. CONCLUSION: While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Schmidt-Lauber C, Hänzelmann S, Schunk S, et al. Kidney outcome after mild to moderate COVID-19. Nephrol Dial Transplant. 2023. PMID: 36657383. doi:10.1093/ndt/gfad008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。